Hayden, P. J. and Roddie, C. and Bader, P. and Basak, G. W. and Bonig, H. and Bonini, C. and Chabannon, C. and Ciceri, F. and Corbacioglu, S. and Ellard, R. and Sanchez-Guijo, F. and Jaeger, U. and Hildebrandt, M. and Hudecek, M. and Kersten, M. J. and Koehl, U. and Kuball, J. and Mielke, S. and Mohty, M. and Murray, J. and Nagler, A. and Rees, J. and Rioufol, C. and Saccardi, R. and Snowden, J. A. and Styczynski, J. and Subklewe, M. and Thieblemont, C. and Topp, M. and Ispizua, A. U. and Chen, D. and Vrhovac, R. and Gribben, J. G. and Kroeger, N. and Einsele, H. and Yakoub-Agha, I (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). ANNALS OF ONCOLOGY, 33 (3). pp. 259-275. ISSN 0923-7534, 1569-8041
Full text not available from this repository. (Request a copy)Abstract
Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. Design: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. Results: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. Conclusions: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CARDIOVASCULAR EVENTS; CLINICAL-DATA; NEUROTOXICITY; MALIGNANCIES; LIMITATIONS; CAR T-cells; B-cell acute lymphoblastic leukemia (B ALL); large B-cell lymphoma (LBCL); multiple myeloma (MM); cytokine release syndrome (CRS); immune effector cell associated neurotoxicity syndrome (ICANS) |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 10:08 |
| Last Modified: | 12 Dec 2023 10:08 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58810 |
Actions (login required)
 |
View Item |
